Follow authorization & medical-necessity rules

Policy states services must meet authorization and medical necessity guidelines; however, no specific prior authorization procedures or criteria are provided in the cited policy excerpts.

No PA statements in this section

No prior authorization statements or provider-level PA steps are specified in the provided document sections.

No explicit PA; tests subject to medical‑necessity review

The policy does not list explicit prior authorization requirements for biomarker testing in these excerpts; use of high-sensitivity troponin and natriuretic peptide testing is described as standard‑of‑care and subject to medical necessity review.

Use listed CPT/HCPCS codes from Section VIII

The policy lists CPT/HCPCS procedure codes for referenced biomarkers in Section VIII for provider billing reference; providers should use these codes when submitting claims.

• Codes listed include: 82550, 82552, 82553, 82554, 82725, 83615, 83625, 83874, 83880, 84450, 84484, 84512, 84588, 86140, 86141.

No PA requirements specified in these sections

No prior authorization requirements are specified elsewhere in the provided document sections; providers must still ensure services meet authorization and medical necessity per the policy header.

No step‑therapy requirements stated

No step therapy rules apply to biomarker testing in the provided excerpts; the policy does not impose sequential treatment/testing prerequisites.

Step therapy not applicable

Step therapy is not applicable for the biomarkers described; the policy instead references guideline preferences (e.g., hs‑cTn) rather than stepwise testing algorithms.

Submit accurate documentation and follow coding rules

The policy requires providers to submit accurate documentation and follow authorization and medical‑necessity rules when billing for biomarker testing; claims may be denied if coding/billing guidelines are not followed.

Document symptom timing, assay type, serial troponins, and 99th‑percentile exceedance

For troponin testing, document timing of symptom onset, the troponin assay type (high‑sensitivity vs contemporary), and serial sampling results including presentation and repeat samples; indicate whether values exceeded the 99th percentile URL.

• Document time of symptom onset or time of presentation if onset unclear.
• Record assay type (hs‑cTn vs contemporary) and each sample time and result.
• Document whether a rise/fall pattern was present and if any value exceeded the 99th percentile URL.

Record troponin sample times and correlate with ECG/imaging

Record exact sampling times: obtain an initial troponin sample at assessment and a follow-up per guideline (presentation and 3–6 hours after symptom onset; additional sampling beyond 6 hours if indicated) and document ECG/imaging correlates and any rising/falling pattern.

• Initial sample at presentation; repeat sample at 3–6 hours after symptom onset.
• Obtain additional samples beyond 6 hours if initial serial troponins are normal but clinical/ECG concern persists.
• Include ECG and imaging findings that support interpretation.

Follow guideline sampling intervals for hs‑cTn and validate LDTs

When using high‑sensitivity troponin assays, obtain an initial sample at assessment and, if multiple samples are taken, a second sample 30 minutes to 3 hours later per NICE and other guideline recommendations; ensure any laboratory‑developed test (LDT) is validated in‑house under CLIA '88.

• If using hs‑cTn and multiple samples, second sample 30–180 minutes after initial per NICE.
• Use 99th‑percentile thresholds or thresholds near assay limit of detection as specified by guidelines.
• Validate LDTs in‑house and follow CLIA '88 high‑complexity test requirements.

Cite supporting guidelines (NICE, ASCP, ACC/AHA) in documentation

Cited guidelines (e.g., NICE, ASCP, ACC/AHA) support use of high‑sensitivity troponin assays for early rule‑out of NSTEMI and recommend against using CK‑MB or myoglobin to diagnose AMI; include these guideline citations in supporting documentation when relevant.

• NICE recommends hs‑cTn use and specific sampling/threshold approaches.
• ASCP recommends using troponin I or T and advises against CK‑MB/myoglobin.
• ACC/AHA/other joint guidelines endorse cTn (I or T), preferably hs‑cTn, for diagnosis of myocardial injury.

Risk of denial for inadequate documentation or inappropriate outpatient testing

Claims may be denied if coding/billing guidelines or current reimbursement policies are not followed; tests performed in outpatient settings that cannot perform adequate MI evaluation (e.g., independent labs or physician offices) may not meet criteria and risk denial.

Document rise/fall and 99th‑percentile threshold to support MI diagnosis

For MI diagnosis, document a rise and/or fall pattern with at least one troponin value above the 99th percentile URL; failure to document serial troponins or the diagnostic threshold may lead to denial of MI‑related testing claims.

• Ensure serial troponin values and timing are recorded and show rise/fall pattern when diagnosing MI.
• Record whether any value exceeded the 99th percentile upper reference limit.

Avoid CK‑MB or myoglobin for primary MI diagnosis (denial risk)

ASCP and other guideline statements recommend against using CK‑MB or myoglobin to diagnose acute MI; reliance on these non‑recommended biomarkers for primary diagnosis may result in claim denial if inconsistent with accepted guidance.

Government policies take precedence over this policy

If this Policy conflicts with any applicable government coverage policy (e.g., LCDs or NCDs), the government policy will take precedence for coverage determinations; providers should check relevant Medicare/Medicaid coverage before submission.

Use troponin I or T (hs‑cTn preferred); avoid myoglobin/CK‑MB for AMI diagnosis

Guidelines recommend using cardiac‑specific troponin I or T (preferably high‑sensitivity assays) for AMI diagnosis and advise against testing for myoglobin or CK‑MB; providers should use recommended troponin assays for primary diagnosis to align with guidance and coverage expectations.

• Use troponin I or T; hs‑cTn assays are preferred for routine clinical use.
• Do not use myoglobin or CK‑MB as primary diagnostic tests when troponin is available.